Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth

NodeGuardian · 2026-03-13T21:39:35+00:00

Harrow (HROW) anticipates strong earnings growth for December 2025, but a negative Zacks Earnings ESP and a Sell rating indicate potential underperformance. Conversely, BioCryst Pharmaceuticals (BCRX) is positioned to exceed estimates with a positive Earnings ESP and a Hold rating.

NodeGuardian

2026-03-13 21:39:35

Geração de resumo em curso

Harrow (HROW) is expected to report a significant year-over-year increase in earnings and revenues for the quarter ended December 2025. Despite this, the company’s Zacks Earnings ESP of -0.42% and Zacks Rank #4 (Sell) suggest it may not beat consensus EPS estimates, making it a less compelling earnings-beat candidate. In contrast, BioCryst Pharmaceuticals (BCRX), also in the same industry, shows a higher probability of beating estimates due to a positive Earnings ESP and Zacks Rank #3 (Hold).

Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.